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Abstract: Background: Gastrointestinal symptomatology is frequent among patients with fibrom-
yalgia, which increases disease burden and lacks specific treatment, either pharmacological or non-
pharmacological. We aimed to evaluate the efficacy and tolerability of a multi-strain probiotic, 
VSL#3®, for the treatment of fibromyalgia-associated gastrointestinal manifestations. Methods: This 
randomized, placebo-controlled trial included 12 weeks of probiotic or placebo treatment followed 
by 12 weeks of follow up. The primary outcome variable was the mean change from the baseline to 
the endpoint in the composite severity score of the three main gastrointestinal symptoms reported 
by patients with fibromyalgia (abdominal pain, abdominal bloating and meteorism). Secondary 
outcome variables were the severity of additional gastrointestinal symptoms, fibromyalgia severity, 
depression, sleep disturbance, health-related quality of life and patients’ overall impression of im-
provement. Results: No differences were found between VSL#3® (n = 54) and the placebo (n = 56) in 
the primary outcome (estimated treatment difference: 1.1; 95% confidence interval [CI]: −2.1, 4.2; p 
= 0.501), or in any of the secondary outcomes. However, responders to VSL#3 were more likely to 
maintain any improvement during the follow-up period compared to responders in the placebo 
arm. Overall, VSL#3 tolerability was good. Conclusion: Our data could not demonstrate any bene-
ficial effects of VSL#3® either on the composite score of severity of abdominal pain, bloating and 
meteorism or in any of the secondary outcome variables. More research is needed to elucidate spe-
cific factors that may predict a favourable response to treatment in patients with fibromyalgia. 
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1. Introduction 
Fibromyalgia is a complex syndrome in that, although its main characteristic is 
chronic generalized musculoskeletal pain, this is accompanied in most patients by other 
symptoms, the most common of which are non-restorative sleep, chronic fatigue, cogni-
tive difficulties and anxious and/or depressive symptoms [1]. It is included within the 
central sensitization syndromes, such as migraine, irritable bowel syndrome (IBS) or tem-
poromandibular disorders, with which it shows a high comorbidity [2]. 
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Gastrointestinal symptoms are very common in patients with fibromyalgia, and 
could be derived from the presence of comorbid IBS or other underlying pathophysiolog-
ical mechanisms [3]. A systematic review reported a pooled prevalence of 51% for func-
tional gastrointestinal disorders and 46% for IBS among patients with fibromyalgia [4]. 
On the other hand, even among patients with fibromyalgia who do not meet the criteria 
to diagnose IBS, the presence of gastrointestinal symptomatology is frequently observed 
[3]. The cause of these symptoms remains unknown, although some studies suggest that 
they could be due to intestinal bacterial overgrowth or intestinal permeability alterations 
[5–7]. A recent study in patients with chronic fatigue syndrome, a pathology that shows a 
broad overlap with fibromyalgia, described an increased likelihood of intestinal dysbiosis 
for these patients.[8] Patients with fibromyalgia also showed an alteration in gut microbi-
ota, although the role of these alterations should be further elucidated [9,10]. 
No specific treatment for alleviating the gastrointestinal symptoms associated with 
fibromyalgia has been studied, despite their frequency and most patients describing them 
as extremely annoying [3,11]. This may explain the frequency with which these patients 
resort to different types of diets, even though their benefits have not been previously 
demonstrated [12–14]. In this regard, the use of probiotics, alone or associated with prebi-
otics (synbiotics), could be an interesting therapeutic approach for managing gastrointes-
tinal symptoms in patients with fibromyalgia. Probiotics have been studied in a variety of 
clinical conditions, including gastrointestinal disorders, dermatological disorders and 
metabolic diseases [15,16]. Among gastrointestinal disorders, the most studied condition 
is IBS, where probiotics seem to exert a favourable response in global symptoms, although 
there are not still enough data to specify which individual probiotics could be more effec-
tive [17]. Probiotics seem to be well tolerated in general [17]. 
Considering the frequent presence of gastrointestinal symptoms in patients with fi-
bromyalgia who might be susceptible to treatment with probiotics, the objective of this 
trial was to assess the efficacy and tolerability of VSL#3®, a multi-strain probiotic, which 
has demonstrated a trend for an overall improvement in the treatment of IBS [18,19] in 
patients with fibromyalgia and gastrointestinal symptomatology. 
2. Results 
2.1. Patient Disposition and Characteristics 
One hundred and ten patients were recruited from May 2018 to November 2019 and 
allocated to either placebo (n = 56) or VSL#3® (n = 54). Twenty-five subjects (44.6%) in the 
placebo group and 28 (51.8%) subjects in the VSL#3® group did not complete the study 
(Figure 1). Fifty-three subjects in each study group were included in the analysis of the 
primary outcome and that of a proportion of responders according to the composite score 
of abdominal pain, bloating and meteorism; secondary efficacy outcomes, including the 
proportion of responders according to the Patient Global Improvement scale (PGI), were 
evaluated in 35 subjects in the placebo group and 28 subjects in the VSL#3® group. All 
randomised subjects were included in the safety analysis. 




Figure 1. Disposition of trial participants. 
Subjects were middle-aged, and the vast majority were women (Table 1). Comorbid-
ity was high, with anxiety/depressive disorder, tension-type headache, craniomandibular 
dysfunction, chronic fatigue syndrome and irritable bowel syndrome present in over 50% 
of the patients (Table 1). Most patients were receiving pharmacological treatment with 
some activity for the symptoms of fibromyalgia. Benzodiazepines, antidepressants, 
NSAIDs, paracetamol and tramadol were mainly used, each in over 30% of the patients; 
one-third of patients were receiving gastroprotectant drugs (Table 1). At baseline, the 
study groups were generally well-balanced regarding demographics and clinical charac-
teristics (Table 1), including the individual gastrointestinal symptoms of abdominal pain, 
abdominal bloating, meteorism, and the composite score of these three symptoms (Table 
2). However, the impact of fibromyalgia as evaluated with the revised fibromyalgia im-
pact questionnaire (FIQR) was greater among placebo-treated patients than in VSL#3®-
treated patients (FIQR total score 75.5 ± 12.3 vs. 70.0 ± 17.8), although the difference was 
not statistically significant. 
Table 1. Demographic and clinical characteristics. 
Variable 
Placebo 
N = 56 
VSL#3® 
N = 54 
Age (years), mean (SD) 55.5 (8.6) 56.0 (7.5) 
Sex (females), n (%) 55 (98.2) 52 (96.3) 
Weight (kg),  71.2 (13.4) 73.3 (17.7) 
Comorbidities a, n (%)   
   Anxiety/depressive disorder 48 (85.7) 45 (83.3) 
   Tension-type headache 40 (71.4) 36 (66.7) 
   Craniomandibular dysfunction 36 (64.3) 36 (66.7) 
   Chronic fatigue syndrome 35 (62.5) 28 (51.9) 
   Irritable bowel syndrome 33 (58.9) 32 (59.3) 
   Migraine 24 (42.9) 30 (55.6) 
Pharmaceuticals 2021, 14, 1063 4 of 14 
 
 
   Hypothyroidism 25 (44.6) 15 (27.8) 
   Osteoarthritis 21 (37.5) 15 (27.8) 
   Rheumatoid arthritis 10 (17.9) 10 (18.5) 
   Hypercholesterolemia 4 (7.1) 9 (16.7) 
   Hypertension 9 (16.1) 9 (16.7) 
   Diabetes mellitus 7 (12.5) 4 (7.4) 
Fibromyalgia diagnosis, mean (SD)   
   Widespread Pain Index (WPI) [range 0–19] 16.5 (2.6) 15.9 (3.0) 
   Symptom Severity Score (SSS) [0–12] 9.7 (1.7) 9.3 (2.0) 
   Fibromyalgia Score (WPI + SSS) [0–31] 26.2 (3.5) 25.3 (4.3) 
a Those with a frequency equal to or greater than 10% in any of the trial arms. SD, standard devia-
tion. 
Table 2. Comparison of the impact of VSL#3® and placebo on gastrointestinal symptoms (ITT-LOCF analysis). 
 
Baseline 
Mean ± SD 
Mean Change (±SD) from 
Baseline to Week 12 
Treatment Difference 
(Placebo Minus VSL#3) 
Gastrointestinal Symptom 
Placebo 
N = 56 
VSL#3® 
N = 54 
Placebo 
N = 53 
VSL#3® 
N = 53 
ETD 95% CI p-Value Cohen’s d 
Primary outcome: composite score 
of Pain + Bloating + Meteorism 20.9 ± 5.6 20.7 ± 5.0 −5.4 ± 6.6 −6.5 ± 9.5 1.1 −2.1 to 4.2 0.501 0.13 
Abdominal pain 6.2 ± 2.5 6.1 ± 2.5 −1.6 ± 3.2 −2.4 ± 3.8 0.8 −0.5 to 2.2 0.228 0.24 
Abdominal bloating 7.8 ± 2.2 7.4 ± 2.1 −2.1 ± 2.9 −2.1 ± 3.6 −0.0 −1.3 to 1.3 0.976 0.01 
Meteorism 6.9 ± 2.8 7.2 ± 2.5 −1.7 ± 2.8 −2.0 ± 3.5 0.3 −1.0 to 1.5 0.668 0.08 
Flatulence 6.5 ± 2.9 6.0 ± 2.3 −1.3 ± 3.2 −1.1 ± 4.0 −0.2 −1.6 to 1.2 0.788 0.05 
Constipation 6.7 ± 3.5 6.1 ± 3.6 −2.4 ± 3.8 −1.6 ± 4.2 −0.8 −2.3 to 0.8 0.323 0.20 
Diarrhoea 2.6 ± 3.5 4.6 ± 3.9 −1.8 ± 3.8 −3.1 ± 4.7 1.3 −0.4 to 2.9 0.131 0.30 
Nausea 3.3 ± 3.2 3.3 ± 3.3 −2.4 ± 3.4 −1.9 ± 4.0 −0.5 −2.0 to 0.9 0.468 0.14 
Vomiting 0.7 ± 1.8 0.8 ± 2.3 −0.5 ± 1.5 −0.6 ± 1.9 0.2 −0.5 to 0.8 0.645 0.09 
Belching 4.2 ± 3.2 4.1 ± 3.5 −0.6 ± 3.3 −1.1 ± 2.8 0.4 −0.8 to 1.6 0.487 0.14 
Dyspepsia 6.2 ± 3.0 6.5 ± 2.9 −2.7 ± 3.8 −3.2 ± 3.5 0.5 −0.9 to 1.9 0.510 0.13 
CI, confidence interval; ETD, estimated treatment difference (positive figures favour VSL#3); ITT, intention-to-treat; FMS, 
fibromyalgia syndrome; LOCF, last observation carried forward; SD, standard deviation. 
2.2. Primary Outcome 
In the intent-to-treat last observation carried forward (LOCF) analysis, at week 12, 
the severity of pain, bloating and meteorism as measured with the composite score was 
reduced by 6.5 points among VSL#3®-treated patients and 5.4 points among placebo-
treated patients; this difference was not statistically different (estimated treatment differ-
ence (ETD): 1.1; 95% confidence interval [CI]: −2.1 to 4.2; p = 0.501) nor clinically relevant 
(Cohen’s d = 0.13). 
2.3. Secondary Outcomes 
2.3.1. Gastrointestinal Symptoms 
There were no statistically significant differences between VSL#3® and placebo in any 
of the individual gastrointestinal symptoms (Table 2). The largest difference was observed 
in diarrhoea, in favour of VSL#3® (ETD: 1.3; 95% CI: −0.4 to 2.9; p = 0.131). All effect sizes 
for the differences between VSL#3® and placebo in the gastrointestinal symptoms were 
trivial, except for a small effect size for abdominal pain and diarrhoea in favour of VSL#3 
and a small effect size for constipation in favour of the placebo. Results of the complete 
case analysis for the primary outcome and the gastrointestinal symptoms were generally 
similar to those of the LOCF approach, except for the largest mean within-group changes 
in the scores (Table 3). 
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Table 3. Comparison of the impact of VSL#3® and placebo on gastrointestinal symptoms (complete case analysis). 
 
Baseline 
Mean ± SD 
Mean Change (±SD) from 
Baseline to Week 12 
Treatment Difference 
(Placebo Minus VSL#3) 
Gastrointestinal Symptom Placebo 
N = 56 
VSL#3® 
N = 54 
Placebo 
N = 53 
VSL#3® 
N = 53 
ETD 95%CI p-Value Cohen’s d 
Primary outcome: composite score 
of Pain + Bloating + Meteorism 20.9 ± 5.6 20.7 ± 5.0 −7.6 ± 6.1 −7.5 ± 8.4 −0.09 −3.7 to 3.5 0.959 0.01 
Abdominal pain 6.2 ± 2.5 6.1 ± 2.5 −2.5 ± 2.9 −2.9 ± 3.4 0.4 −1.2 to 2.0 0.620 0.13 
Abdominal bloating 7.8 ± 2.2 7.4 ± 2.1 −3.2 ± 2.9 −2.5 ± 3.3 −0.7 −2.3 to 0.9 0.373 0.23 
Meteorism 6.9 ± 2.8 7.2 ± 2.5 −2.0 ± 3.0 −2.2 ± 3.3 0.2 −1.4 to 1.8 0.789 0.07 
Flatulence 6.5 ± 2.9 6.0 ± 2.3 −1.5 ± 3.3 −1.8 ± 5.0 0.3 −1.5 to 2.1 0.759 0.08 
Constipation 6.7 ± 3.5 6.1 ± 3.6 −3.2 ± 3.6 −2.6 ± 4.1 −0.6 −2.6 to 1.3 0.522 0.17 
Diarrhoea 2.6 ± 3.5 4.6 ± 3.9 −1.2 ± 3.3 −2.5 ± 4.5 1.3 −0.8 to 3.4 0.213 0.34 
Nausea 3.3 ± 3.2 3.3 ± 3.3 −2.8 ± 3.1 −2.6 ± 2.7 −0.2 −1.7 to 1.3 0.787 0.07 
Vomiting 0.7 ± 1.8 0.8 ± 2.3 −0.2 ± 1.0 −0.5 ± 1.3 0.4 −0.2 to 1.0 0.231 0.31 
Belching 4.2 ± 3.2 4.1 ± 3.5 −1.3 ± 2.9 −1.6 ± 2.4 0.3 −1.1 to 1.7 0.678 0.11 
Dyspepsia 6.2 ± 3.0 6.5 ± 2.9 −3.2 ± 3.4 −3.8 ± 3.2 0.7 −1.0 to 2.3 0.444 0.20 
CI, confidence interval; ETD, estimated treatment difference (positive figures favour VSL#3); FMS, fibromyalgia syn-
drome; SD, standard deviation. 
In the intent-to-treat population and using an LOCF approach, by week 12, 27 out of 
the 53 (50.9%) patients showed a reduction equal to or greater than 30% in the composite 
score of abdominal pain, bloating and meteorism in the VSL#3® group, compared to 22 of 
the 53 (41.5%) in the placebo group (relative risk [RR]: 1.23; 95% CI: 0.81 to 1.86). The 
proportion of responders according to the PGI was 22.2% and 26.4% for VSL#3- and pla-
cebo-treated patients, respectively (RR: 0.86; 95% CI: 0.44 to 1.68) (Figure 2). 
 
Figure 2. Proportion of responders to treatment. 
Among the patients who responded to treatment at week 12 according to the reduc-
tion in the composite score of abdominal pain, bloating and meteorism, after discontinu-
ing the study treatment, the composite score increased by over four points during the 12-
week follow-up extension in the placebo group and by over one point in the VSL#3® 
group, with an ETD of 2.8 points (95% CI: 0.0 to 5.6; p = 0.048) (Figure 3). 




Figure 3. Composite score of abdominal pain, bloating and meteorism after discontinuing the study 
treatment. 
There were no relevant differences in the baseline characteristics between responders 
and non-responders in either the total sample or in the VSL#3® and placebo groups (data 
not shown). 
2.3.2. The Effect on Other Symptoms of Fibromyalgia and Quality of Life 
Overall, the severity of fibromyalgia was reduced in both study groups, but to a 
greater extent among placebo-treated patients, although the differences between the two 
study groups were not statistically significant (ETD: −5.2; 95% CI: −12.0 to 1.6; p = 0.128; 
Cohen’s d: 0.40). Except for stiffness, which improved to a significantly greater extent with 
the placebo than with VSL#3® (ETD: −1.5; 95% CI: −2.8 to 0.1; p = 0.0304; Cohen’s d: 0.56), 
there were no significant differences in the changes from baseline in the core symptoms 
of fibromyalgia, sleep impairment, depressive symptoms or quality of life between 
VSL#3® and the placebo (Table 4). 
Table 4. Comparison of the impact of VSL#3® and placebo on fibromyalgia, sleep, depression and quality of life. 
 Baseline (Mean ± SD) 
Mean Change (±SD) from 
Baseline to Week 12 
Treatment Difference 
(Placebo Minus VSL#3) 
Outcome Placebo 
N = 56 
VSL#3® 
N = 54 
Placebo 
N = 35 
VSL#3® 
N = 28 
ETD 95% CI p-Value Cohen’s d 
FIQR-total 75.5 ± 12.3 70.0 ± 17.8 −12.5 ± 14.1 −7.2 ± 12.5 −5.2 −12.0 to 1.6 0.128 0.40 
FIQR-pain 8.0 ± 1.6 7.8 ± 1.6 −0.7 ± 2.0 −0.9 ± 2.3 0.3 −0.8 to 1.3 0.611 0.13 
FIQR-energy 7.9 ± 2.4 7.6 ± 2.4 −0.6 ± 3.2 −1.0 ± 2.9 0.4 −1.2 to 1.9 0.635 0.12 
FIQR-stiffness 8.1 ± 2.1 7.3 ± 2.5 −1.7 ± 2.9 −0.3 ± 2.3 −1.5 −2.8 to 0.1 0.034 0.56 
ISI total 19.9 ± 4.6 17.3 ± 7.0 −1.2 ± 4.0 −1.7 ± 5.9 0.5 −2.0 to 3.0 0.702 0.10 
PHQ-9 17.4 ± 5.6 16.3 ± 6.3 −2.5 ± 4.2 −2.2 ± 7.2 −0.3 −3.4 to 2.8 0.846 0.05 
SF-36 PCS * 28.4 ± 7.0 27.9 ± 6.3 2.2 ± 6.3 4.5 ± 8.0 −2.3 −5.9 to 1.3 0.211 0.33 
SF-36 MCS * 32.1 ± 11.8 32.6 ± 12.8 1.9 ± 12.2 0.8 ± 12.4 1.1 −5.3 to 7.4 0.740 0.09 
* The number of observed cases at week 12 was N = 35 and N = 27 for placebo and VSL#3, respectively. CI, confidence 
interval; ETD, estimated treatment difference (positive figures favour VSL#3); FIQR, Revised Fibromyalgia Impact Ques-
tionnaire; ISI, Insomnia Severity Inventory; MCS, Mental Component Score; PHQ-9, 9-item Patient Health Questionnaire; 
PCS, Physical Component Score; SD, standard deviation; SF-36, Short-Form Health-Survey. 
2.4. Tolerability 
One-third of the patients in each study group reported at least one adverse event. 
Seven (13.0%) patients in the VSL#3® group and six (10.7%) in the placebo group discon-
tinued the treatment due to adverse events. The vast majority of the adverse events were 
Pharmaceuticals 2021, 14, 1063 7 of 14 
 
 
gastrointestinal related, with some differences between the two study groups in the ad-
verse event profile. Abdominal distension was more frequent among VSL#3®-treated pa-
tients, whereas upper abdominal pain was more frequent among placebo-treated patients; 
however, none of the differences was statistically significant (Table 5). 
Table 5. Safety and tolerability profiles of VSL#3® and placebo. 
Outcome [N (%)] 
Placebo 
N = 56 
VSL#3® 
N = 54 
p-Value 
At least one adverse event 19 (33.9) 20 (37.0) 0.733 
Treatment discontinuation due to ad-
verse events 
6 (10.7) 7 (13.0) 0.714 
Serious adverse events 0 (0.0) 0 (0.0) NA 
Most frequent adverse events a (inci-
dence ≥ 3%) 
   
   Abdominal distension 1 (1.8) 5 (9.3) 0.110 
   Flatulence 3 (5.4) 5 (9.3) 0.490 
   Abdominal pain 3 (5.4) 3 (5.6) 1.000 
   Constipation 4 (7.1) 3 (5.6) 1.000 
   Diarrhoea 0 (0.0) 2 (3.7) 0.240 
   Vomiting 0 (0.0) 2 (3.7) 0.240 
   Nausea 3 (5.4) 2 (3.7) 1.000 
   Disease worsening 0 (0.0) 2 (3.7) 0.240 
   Dyspepsia 3 (5.4) 0 (0.0) 0.240 
   Headache 2 (3.6) 0 (0.0) 0.490 
   Upper abdominal pain 4 (7.1) 0 (0.0) 0.120 
   Swelling 2 (3.6) 0 (0.0) 0.490 
   Influenza 2 (3.6) 0 (0.0) 0.490 
a Adverse events were coded with the Medical Dictionary for Regulatory Activities (MedRA) and 
are presented as preferred terms. NA = not applicable as the data did not fulfil the criteria required 
to perform a Fisher’s test. 
3. Discussion 
Overall, our data could not demonstrate any beneficial effects of VSL#3® either on the 
composite score of severity of abdominal pain, bloating and meteorism or in any of the 
secondary outcome variables. This lack of benefit can be potentially attributed to several 
factors, including the elevated placebo response, the high proportion of patients who 
withdrew from the study, and the presence of rather complicated mechanisms underlying 
the gastrointestinal manifestations in fibromyalgia. 
The relevance of the placebo effect in fibromyalgia clinical trials is substantial and 
has been investigated in several systematic reviews and meta-analyses [20–22]. It has been 
estimated that the mean placebo effect for pain reduction in patients with fibromyalgia is 
30.8% when considering a 30% pain reduction, and 18.8% when considering a 50% pain 
reduction [20,21]. A recent meta-analysis found that, in relation to patients that received 
no treatment, fibromyalgia patients receiving placebo experienced significant improve-
ment not only in pain, but also in fatigue, sleep quality, physical function and FIQ total 
score [22]. In our study, the proportion of placebo responders for the main outcome vari-
able was 50.9%. Similar placebo effect rates have been described in clinical trials evaluat-
ing probiotics in patients with IBS. In their review, Rogers and Mousa indicated the pres-
ence of a high placebo effect among patients with IBS ranging between 30% and 50%. 
Several mediators of the placebo effect, particularly in patients with functional somatic 
disorders, have been suggested, including Pavlovian conditioning, belief outcomes, and 
patient expectations, among other factors [23]. 
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The dropout rate was also disproportionately high. Nocebo effect is also very rele-
vant in fibromyalgia clinical trials, and it has been estimated to represent between 9% and 
11% of patient dropouts [21,24]. Consistent with these estimations, the percentage of pla-
cebo-treated patients in our study that withdrew due to tolerability issues was 10.7% of 
the sample, slightly less than the dropout rate in the VSL#3® group, which was of 12%. 
However, 17 (31.5%) patients in the VSL#3®-treated group and 15 (26.8%) in the placebo-
treated group withdrew due to reasons unrelated to tolerability and/or efficacy issues, 
mainly loss of follow up; the percentage of withdrawals was similar across participating 
centres. 
The effects of probiotics on human health seem to be related to different effects, such 
as a decrease in inflammation, decrease in intestinal permeability, modification of the in-
testinal microbiota, and metabolism modulation. These effects are mediated by multiple 
mechanisms of action, including the colonization and normalization of perturbed intesti-
nal microbial communities, competitive exclusion of pathogens, modulation of enzymatic 
activities and production of volatile fatty acids. Nevertheless, it is important to highlight 
that the mechanisms underlying the exacerbation of gastrointestinal manifestations in fi-
bromyalgia appear to be far more complex and extend beyond the possible small intesti-
nal bacterial overgrowth, gut microbiota alterations or symbiosis [3]. Therefore, this may 
provide another possible explanation for the lack of benefit of VSL#3 on the primary effi-
cacy outcome. More research is needed to further understand the specific patient charac-
teristics that may predict a favourable response to VSL#3®. 
Interestingly, VSL#3-treated patients who were considered as responders to treat-
ment according to the primary outcome variable maintained the degree of improvement 
obtained after the treatment period during the follow-up period, whereas in placebo-
treated patients who were considered as responders, the improvement decreased during 
the follow-up period. This suggests that at least a subgroup of patients obtained a benefit 
from VSL#3® treatment. Unfortunately, we were not able to identify any characteristic that 
could differentiate placebo- from VSL#3®-responders. 
In the last five years, the efficacy of probiotics in the treatment of IBS has been eval-
uated in several systematic reviews and meta-analyses [17,25–27]. These reviews reached 
a common conclusion that probiotics seem to be beneficial for IBS symptoms and that their 
tolerability is generally good, although more information is needed in relation to probiotic 
type, probiotic dosage and treatment length. With one exception [27], they also agree in 
considering that multi-strain probiotics seem to be preferable over single-strain probiotics. 
The use of probiotics in the management of IBS has been recently revised by the 
American Gastroenterological Association in a technical review that found that, although 
data concerning the potential efficacy of probiotics on the management of IBS are substan-
tial, no single strain or combination has been studied in a sufficiently rigorous manner 
[28]. For this reason, the American Gastroenterological Association advocates the use of 
probiotics for the treatment of IBS only in the context of a clinical trial [29]. 
VSL#3® has been the object of two meta-analyses in the treatment of IBS. The first 
one, published in 2018, evaluated the efficacy and tolerability of VSL3#3® for the treatment 
of IBS [18]; the authors concluded that, although a trend for global overall improvement 
was observed, no significant differences with placebo were found for specific symptoms 
such as abdominal pain, bloating or stool consistency. Probiotic-associated side effects 
were detailed only in one of the five clinical trials included in the meta-analysis and re-
ported a more frequent worsening of the gastrointestinal symptoms in VSL#3®-treated 
patients than in placebo-treated patients. In our study, almost all side-effects reported by 
patients who received VSL#3® were also related to the worsening of the previous gastro-
intestinal symptoms (Table 5). We would like to note that some authors have reported 
that the formulation of VSL#3 used in the studies conducted prior to 2016 is not the same 
as the one used here; thus, the results reported in this meta-analysis could be referred to 
that formulation and not the one we used in our study [30]. The second meta-analysis was 
based on the tolerability of VSL#3® in any clinical condition, which included IBS, obesity, 
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ulcerative colitis, and early menopause, concluding that the safety profile of VSL#3® was 
not significantly different from the placebo, and was similar to that of other probiotics 
[19]. However, there are uncertainties about this meta-analysis because the actual number 
of patients examined was too small and the pathologies and the probiotic dosages too 
heterogeneous. 
To the best of our knowledge, only one study has been published evaluating the use 
of probiotics in the treatment of fibromyalgia [31]. The objective of this randomised, pla-
cebo-controlled trial, which also used a multi-strain probiotic, was to investigate the po-
tential efficacy of the probiotic on the cognition, emotional symptoms and functional state 
of the patients. Thus, we cannot establish any comparison in relation to our primary ob-
jective, which was to assess the gastrointestinal symptomatology of the patients. How-
ever, the authors assessed other variables that we also evaluated, such as depression, anx-
iety, fibromyalgia pain and impact and health-related quality of life, As in our case, no 
significant differences were found between the probiotic and placebo in relation to any of 
these outcomes. 
Our study has some limitations. The high dropout rate and its impact on the study 
estimates because of the missing data as well as the placebo effect in our study were rela-
tively high, prompting cautious interpretation of the study findings. Although we per-
formed a secondary analysis using a complete case approach in order to limit the influence 
of the imputation method to handle missing data, it is important to bear in mind that 
complete case analysis is appropriate only when the participants in the analysis can be 
regarded as a random sample of the study population (i.e., when the missing mechanism 
is missing completely at random) [32], which cannot be assumed to be the case in our 
study; in addition, complete case analysis tends to overestimate treatment effects. There-
fore, complete case analysis can only be considered as a sensitivity analysis. In addition, 
due to the lack of a validated scale for measuring our primary outcome, we had to use an 
ad hoc instrument to assess the severity of gastrointestinal symptoms. Additionally, the 
lack of sample size calculation due to the absence of published data on the primary out-
come measure may have prevented us from adequately controlling the power in the cur-
rent study. Finally, we did not investigate the composition of patients’ microbiota either 
at the beginning or the end of the trial; this would have been a worthwhile approach, since 
different experimental and clinical studies have shown that multi-train probiotics can im-
prove health by modifying the gut microbiota composition [33–36]. 
4. Materials and Methods 
4.1. Study Design 
In this study, a randomised double-blind placebo-controlled trial evaluating the effi-
cacy and tolerability of VSL#3® in the treatment of patients with fibromyalgia and associ-
ated gastrointestinal symptomatology was conducted. VSL#3® (manufactured for Actial 
Farmaceutica Srl) is a high-concentration multi-strain probiotic mix, commercially avail-
able in 450 billion CFU/sachet, containing the following: i) one strain of Streptococcus ther-
mophilus BT01; ii) three strains of Bifidobacteria: B. breve BB02, B. animalis subsp. lactis BL03 
(previously identified as B. longum BL03) and B. animalis subsp. lactis BI04 (previously iden-
tified as B. infantis BI04); and iii) four strains of Lactobacilli: L. acidophilus BA05, L. planta-
rum BP06, L. paracasei BP07 and L. helveticus BD08 (previously identified as L. delbrueckii 
subsp. bulgaricus BD08) [37]. The composition of the placebo was maltose, cornstarch and 
silicon dioxide 
The treatment was administered during a 12-week period, and the participants were 
followed for an additional 12-week period in order to follow evolution after treatment. 
The trial protocol was approved both by the Biomedical Research Ethics Committee of the 
province of Granada (Granada, Spain) and by the Ethics Committee of the Catholic Uni-
versity of Murcia (Murcia, Spain), the two cities where the trial was carried out. Written 
Pharmaceuticals 2021, 14, 1063 10 of 14 
 
 
informed consent was obtained from every subject before inclusion in the study. The trial 
was registered at ClinicalTrials.gov with the identifier NCT04256785. 
4.2. Participants 
Patients were recruited from several fibromyalgia associations who regularly at-
tended the two outpatient clinics where the trial was performed. 
The inclusion criteria were the following: a) diagnosis with fibromyalgia, confirmed 
at the screening of patients using the ACR 2016 criteria [38]; b) 18 years of age or older; c) 
agreement to voluntarily participate in the study by signing informed consent; d) willing-
ness to, with no need under medical criteria, maintain the treatment previously received 
for fibromyalgia, both of pharmacological and non-pharmacological types, with no 
change in life habits especially regarding habitual diet during the trial’s duration; and e) 
regular suffering (two or more times per week) from three or more of the following symp-
toms: abdominal pain, abdominal bloating, meteorism, flatulence, nausea, dyspepsia, 
eructation, constipation and/or diarrhoea. 
The exclusion criteria were as follows: a) suffering from severe mental illness other 
than major depression; b) suffering from severe renal, hepatic or cardiovascular organic 
disease that, at the discretion of the investigator, could have interfered with participation 
in the study; c) suffering from any chronic gastrointestinal disease other than IBS, such as 
inflammatory bowel disease, active gastroduodenal ulcer or colorectal carcinoma; and d) 
pregnancy or breastfeeding. All of the mentioned diseases were required to have been 
diagnosed by a physician. 
4.3. Study Assessments 
The severity of the following types of gastrointestinal symptoms was evaluated using 
a 10-point Visual Analogue Scale (VAS): abdominal pain, abdominal bloating, meteorism, 
flatulence, constipation, diarrhoea, nausea, eructation and dyspepsia. 
Secondary assessments were the following: 
(a) The Revised Fibromyalgia Impact Questionnaire (FIQR) [39]: This instrument was 
created to assess the overall symptoms related to fibromyalgia. The total score of the FIQR 
ranges from 0 to 100, and the higher the score, the greater the severity of fibromyalgia. 
The validated Spanish version was used [40]. 
(b) The 9-item Patient Health Questionnaire (PHQ-9): The objective of this question-
naire is to evaluate depressive symptoms. Its total score ranges from 0 to 27 points; the 
higher the score, the greater the severity of the depression. Since depression is also a 
symptom frequently associated with fibromyalgia, it was used to check whether an even-
tual improvement in gastrointestinal symptoms is reflected in an improvement in depres-
sive symptomatology. A validated Spanish version of the questionnaire was used [41]. 
(c) The Insomnia Severity Inventory (ISI): This is a brief questionnaire which assesses 
the severity of insomnia. Its total score ranges from 0 to 28 points; the higher the score, the 
greater the severity of insomnia. The validated Spanish version of the questionnaire was 
used [42]. 
(d) The Short-Form Health-Survey SF-36: This multi-item generic health survey aims 
to evaluate general health concepts not specific to any age, disease or treatment group and 
measures eight health domains: physical functioning, physical role limitations, bodily 
pain, general health perceptions, vitality, social functioning, emotional limitations and 
mental health. These domains yield two summary measures: the Physical Component 
Summary (PCS) and the Mental Component Summary (MCS). The validated Spanish ver-
sion was applied [43]. 
(e) A seven-point, Likert-type scale, the Patient Global Improvement Scale, was used 
to assess the relief of patients’ general symptomatology 
  




At the time of screening, demographic and clinical data from each patient were col-
lected, and the fibromyalgia diagnosis was confirmed. Then, each patient was allocated 
either to VSL#3® or the matching placebo; the treatment was administered as two sachets 
of study products twice a day for twelve consecutive weeks. Each sachet of VSL#3® con-
tained 450 billion CFU of live freeze-dried bacteria in powder form (Lot. No. 709002, 
709003, 802112, 802113). Patients were randomised in a 1:1 ratio to one of the two treat-
ment groups using a random number generator. 
On the day of initiation of treatment, the following questionnaires were adminis-
tered: VAS of abdominal pain, abdominal bloating, meteorism, flatulence, constipation, 
diarrhoea, nausea, eructation and dyspepsia; FIQR; ISI; PHQ-9; PGI; and SF-36. 
Visual analogue scales of gastrointestinal symptomatology were filled in weekly by 
the patients during the first 4 weeks of the trial and every 2 weeks between weeks 4 and 
12 of the trial. At week 12, FIQR, ISI, PHQ-9 and SF-36 were also completed; PGI was filled 
in on weeks 4, 8 and 12. 
At the end of the treatment period, patients entered into a follow-up period and were 
monitored at 4, 12 and 24 weeks thereafter; in these visits, the VAS of gastrointestinal 
symptoms, FIQR, PGI and SF-36 were completed. 
Adverse effects potentially associated with treatment were collected at each visit 
through an open-ended question system. During the 12 weeks of treatment, the medica-
tion packages were collected to control therapeutic compliance. 
4.5. Statistical Analysis 
Given the absence of previous intervention studies in this area and, in general, lim-
ited information on this aspect of fibromyalgia, this was considered a pilot study. Thus, 
the calculation of the sample size was based on the feasibility of recruiting them. The re-
cruitment of 110 patients was estimated as a reasonably attainable goal considering the 
volume of patients attending each one of the two participating centres. 
The primary outcome variable was the mean change from baseline to endpoint in the 
composite score of the three main gastrointestinal symptoms reported by patients with 
fibromyalgia, i.e., abdominal pain, abdominal bloating and meteorism, as evaluated with 
the 10-point VAS. We selected the primary outcome variable considering the most fre-
quent gastrointestinal symptoms previously observed in patients with fibromyalgia [3], 
which are also the most common ones in IBS. Secondary outcomes were the mean changes 
from baseline to endpoint in the scores of the FIQR, ISI, PHQ-9 and SF-36. In addition, the 
proportion of responders regarding gastrointestinal symptoms was calculated in two 
ways: the proportion of patients with a reduction equal to or greater than 30% in the com-
posite score of abdominal pain, bloating and meteorism, and the proportion of patients 
who were highly or very highly improved (i.e., a score of 1 or 2) according to the PGI. 
All patients who had a postbaseline evaluation were included in the efficacy anal-
yses, and missing data were imputed using the LOCF approach. A complete case analysis 
was also performed for the analysis of the mean changes in the scores of the gastrointes-
tinal symptoms. The results were analysed by applying Student’s t-test to independent 
samples in order to compare the data between the subjects who received the placebo and 
those who received the active product, as well as to compare the data in the subgroups of 
patients treated with the placebo and with VSL#3®. The proportion of responders and 
other categorical variables were compared using the χ2 test or Fisher’s exact test, as ap-
propriate. Values lower than 0.05 were considered significant. Effect sizes were calculated 
using Cohen’s d and interpreted as trivial if they were <0.2, small if they were between 0.2 
and <0.5, medium if they were between 0.5 and <0.8 and large if they were ≥0.8. All anal-
yses were performed using SPSS version 22. 
  




In summary, although VSL#3® displayed favourable safety and tolerability profiles 
in patients with fibromyalgia, it did not improve their gastrointestinal or fibromyalgia 
symptomatology compared to the placebo. However, the maintenance of the benefit 
among VSL#3® responders and not among placebo responders suggests that some pa-
tients could benefit from treatment with this probiotic. More research is still needed to 
further elucidate the specific factors that may predict a favourable response to treatment 
with VSL#3® in patients with fibromyalgia. 
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